NSCLC

[Cancer Gene Therapy] Scientists revealed that the expression of ALKBH5 was increased in NSCLC and increased expression of ALKBH5 worsened the prognosis of patients with NSCLC.

[Gene Therapy] The authors reported how nuclear factor erythroid 2-related factor 2 disruption led to collateral damage in the form of CRISPR-mediated exon skipping.

[Cell Death Discovery] Researchers performed GEO dataset analysis and identified that claudin1 was a critical regulator of epidermal growth factor receptor tyrosine kinase inhibitors resistance in NSCLC cells.

[npj Precision Oncology] Investigators established lorlatinib intermediate resistant cells from a patient-derived cell model. Glycogen synthase kinase 3 (GSK3) inhibitions significantly suppressed lorlatinib intermediate resistant cell growth.

[Seminars in Cancer Biology] The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses.

[Foundation Medicine, Inc.] Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC.